{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:55:10Z","timestamp":1790009710076,"version":"4.0.1"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The activity of albaconazole (UR-9825; J. Uriach &amp; Ci\u0301a. S.A., Barcelona, Spain) was compared to that of fluconazole against 12 isolates of\n            <jats:italic>Cryptococcus neoformans<\/jats:italic>\n            in vitro and against 1 isolate in vivo in a rabbit model of cryptococcal meningitis. Albaconazole was 100-fold more potent in vitro than fluconazole on a per-weight basis and was fungicidal at potentially relevant concentrations for two isolates. MICs ranged from \u22640.0012 to 1.25 \u03bcg\/ml, with the MICs for most isolates being between 0.039 and 0.156 \u03bcg\/ml. Isolates were from human immunodeficiency virus (HIV)-infected and non-HIV-infected patients and were of serotypes A, B, and C; and the fluconazole MICs for some of the isolates were elevated. Infected rabbits were treated with either fluconazole or albaconazole at dosages ranging from 5 to 80 mg\/kg of body weight\/day. The peak concentrations of albaconazole in serum and cerebrospinal fluid (CSF) averaged 4.14 and 0.62 \u03bcg\/ml, respectively, in animals receiving 80 mg\/kg\/day. Comparison of the concentrations in serum and CSF suggested a level of CSF penetration of approximately 15%. Despite limited penetration into the subarachnoid space, at all three doses tested albaconazole was as effective as fluconazole for the treatment of cryptococcal meningitis in rabbits.\n          <\/jats:p>","DOI":"10.1128\/aac.48.2.384-387.2004","type":"journal-article","created":{"date-parts":[[2004,1,24]],"date-time":"2004-01-24T23:46:39Z","timestamp":1074987999000},"page":"384-387","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":34,"title":["In Vitro and In Vivo Efficacies of the New Triazole Albaconazole against\n            <i>Cryptococcus neoformans<\/i>"],"prefix":"10.1128","volume":"48","author":[{"given":"J. L.","family":"Miller","sequence":"first","affiliation":[{"name":"Department of Medicine, Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. A.","family":"Schell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. A.","family":"Wills","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Toffaletti","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boyce","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"D. K.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bartroli","sequence":"additional","affiliation":[{"name":"Drug Discovery, J. Uriach &amp; Cia, Palau-solita\u0300 i Plegamans, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Perfect","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1021\/jm9707277","volume":"41","year":"1998","unstructured":"Bartroli, J., E. Turmo, M. Alguero, E. Boncompte, M. L. Vericat, L. Conte, J. Ramis, M. Merlos, J. Garcia-Rafanell, and J. Forn. 1998. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. J. Med. Chem.41:1869-1882.","journal-title":"J. Med. Chem."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197907193010303"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.22.2.157-160.1985"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJM199102283240902","volume":"324","year":"1991","unstructured":"Bozzette, S. A., R. A. Larsen, and J. Chin. 1991. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N. Engl. J. Med.324:580-584.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390100107024"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198708063170602"},{"key":"e_1_3_2_8_2","unstructured":"Galgiani J. N. M. S. Barlett M. A. Ghannoum A. Espinel-Ingroff M. V. Lancaster F. C. Odds M. A. Pfaller M. G. Rinaldi and T. J. Walsh. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts p. 1-29. Approved standard 17-9. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199712000-00010"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/322597"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.5.975-a"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.8.1910"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/146.3.429"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.6.751"},{"key":"e_1_3_2_15_2","first-page":"177","volume":"101","year":"1980","unstructured":"Perfect, J. R., S. D. R. Lang, and D. T. Durack. 1980. Chronic cryptococcal meningitis; a new experimental model in rabbits. Am. J. Pathol.101:177-194.","journal-title":"Am. J. Pathol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.4.579"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/33.1.73","volume":"33","year":"1994","unstructured":"Perfect, J. R., and K. A. Wright. 1994. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. J. Antimicrob. Chemother.33:73-81.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.10.1735"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503163321102"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.283"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201093260202"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2630"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/infdis\/168.2.508","volume":"168","year":"1993","unstructured":"Velez, J. D., R. Allendoerfer, M. Luther, M. G. Rinaldi, and J. R. Graybill. 1993. Correlation of in vitro azole susceptibility with in vitro response in a murine model of cryptococcal meningitis. J. Infect. Dis.168:508-510.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.322"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/26.3.387"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.2.384-387.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.2.384-387.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:19:55Z","timestamp":1645467595000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.2.384-387.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1128\/AAC.48.2.384-387.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.2.384-387.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]},"assertion":[{"value":"2003-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-10-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}